M72/AS01E vaccine in an ongoing Phase IIb trial reduced the incidence of pulmonary tuberculosis disease.- GSK

GSK and Aeras reported that GSK�s M72/AS01E candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection in an ongoing phase IIb clinical trial testing. These primary results published in the New England Journal of Medicine after two years of trial demonstrate an overall vaccine efficacy of 54%, with varied response rates observed in different demographic sub-groups. The candidate vaccine had an acceptable safety and reactogenicity profile.

See- "Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis"-Olivier Van Der Meeren, M.D., Mark Hatherill, M.D., Videlis Nduba, M.B., Ch.B., M.P.H., Robert J. Wilkinson, F.Med.Sci., Monde Muyoyeta, M.B., Ch.B., Ph.D., Elana Van Brakel, M.B., Ch.B et al.-September 25, 2018 DOI: 10.1056/NEJMoa1803484.